CN112051346A - 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 - Google Patents
一种同时测定茚达特罗和格隆溴铵含量的hplc方法 Download PDFInfo
- Publication number
- CN112051346A CN112051346A CN202011018331.XA CN202011018331A CN112051346A CN 112051346 A CN112051346 A CN 112051346A CN 202011018331 A CN202011018331 A CN 202011018331A CN 112051346 A CN112051346 A CN 112051346A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- indacaterol
- glycopyrronium bromide
- test solution
- hplc method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940020900 indacaterol and glycopyrronium bromide Drugs 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000004128 high performance liquid chromatography Methods 0.000 title claims abstract description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 51
- 238000010828 elution Methods 0.000 claims abstract description 19
- 230000035945 sensitivity Effects 0.000 claims abstract description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000000945 filler Substances 0.000 claims abstract description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000004007 reversed phase HPLC Methods 0.000 claims abstract description 3
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 3
- 239000012085 test solution Substances 0.000 claims description 56
- 239000012088 reference solution Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 11
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 10
- 238000007865 diluting Methods 0.000 claims description 9
- 238000010812 external standard method Methods 0.000 claims description 9
- 238000000691 measurement method Methods 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229960002462 glycopyrronium bromide Drugs 0.000 abstract description 14
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract description 13
- 229960004078 indacaterol Drugs 0.000 abstract description 11
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 abstract description 11
- 238000012827 research and development Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000003002 pH adjusting agent Substances 0.000 abstract description 3
- 238000005220 pharmaceutical analysis Methods 0.000 abstract description 2
- 239000008363 phosphate buffer Substances 0.000 description 15
- 230000014759 maintenance of location Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 229960004735 indacaterol maleate Drugs 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- IREJFXIHXRZFER-PCBAQXHCSA-N indacaterol maleate Chemical compound OC(=O)\C=C/C(O)=O.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 IREJFXIHXRZFER-PCBAQXHCSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-M 3',5'-cyclic AMP(1-) Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-M 0.000 description 1
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 1
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000017926 CHRM2 Human genes 0.000 description 1
- 102000017925 CHRM3 Human genes 0.000 description 1
- 101150060249 CHRM3 gene Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 101150012960 Chrm2 gene Proteins 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- -1 indacaterol maleate glycopyrronium bromide compound Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940125389 long-acting beta agonist Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/30—Control of physical parameters of the fluid carrier of temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/60—Construction of the column
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/047—Standards external
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
- G01N2030/324—Control of physical parameters of the fluid carrier of pressure or speed speed, flow rate
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Steroid Compounds (AREA)
Abstract
Description
保留时间 | 峰面积 | 峰高 | 理论塔板数 | 拖尾因子 |
1.804min | 195 | 84 | 9295 | 1.2 |
2.251min | 2118 | 581 | 7035 | 1.2 |
保留时间 | 峰面积 | 峰高 | 理论塔板数 | 拖尾因子 |
5.598min | 58 | 8 | 14695 | 1.3 |
8.326min | 2007 | 367 | 5654 | 1.2 |
保留时间 | 峰面积 | 峰高 | 理论塔板数 | 拖尾因子 |
6.627min | 93 | 11 | 16405 | 1.2 |
9.721min | 2195 | 215 | 21697 | 1.4 |
保留时间 | 峰面积 | 峰高 | 理论塔板数 | 拖尾因子 |
5.188min | 74 | 11 | 13504 | 1.3 |
7.847min | 1757 | 191 | 18206 | 1.4 |
保留时间 | 峰面积 | 峰高 | 理论塔板数 | 拖尾因子 |
5.670min | 323 | 38 | 12951 | 1.5 |
8.520min | 2748 | 240 | 23365 | 1.5 |
保留时间 | 峰面积 | 峰高 | 理论塔板数 | 拖尾因子 |
5.168min | 324 | 42 | 10650 | 1.4 |
7.788min | 2747 | 269 | 14067 | 1.4 |
保留时间 | 峰面积 | 峰高 | 理论塔板数 | 信噪比 |
5.164min | 1.9 | 0.26 | 12372 | 13.7 |
7.786min | 2.8 | 0.28 | 16343 | 16.7 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011018331.XA CN112051346A (zh) | 2020-09-24 | 2020-09-24 | 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011018331.XA CN112051346A (zh) | 2020-09-24 | 2020-09-24 | 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112051346A true CN112051346A (zh) | 2020-12-08 |
Family
ID=73604676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011018331.XA Pending CN112051346A (zh) | 2020-09-24 | 2020-09-24 | 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112051346A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102665680A (zh) * | 2009-12-23 | 2012-09-12 | 奇斯药制品公司 | 用于copd的气雾剂制剂 |
US20150182450A1 (en) * | 2013-12-30 | 2015-07-02 | Chiesi Farmaceutici S.P.A. | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
CN104955449A (zh) * | 2013-01-31 | 2015-09-30 | 普罗索尼克斯有限公司 | 用于吸入治疗的多组分结晶颗粒 |
GB201615910D0 (en) * | 2016-09-19 | 2016-11-02 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
CN109789126A (zh) * | 2016-09-19 | 2019-05-21 | 墨西哥氟石股份公司 | 药物组合物 |
-
2020
- 2020-09-24 CN CN202011018331.XA patent/CN112051346A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102665680A (zh) * | 2009-12-23 | 2012-09-12 | 奇斯药制品公司 | 用于copd的气雾剂制剂 |
CN104955449A (zh) * | 2013-01-31 | 2015-09-30 | 普罗索尼克斯有限公司 | 用于吸入治疗的多组分结晶颗粒 |
US20150182450A1 (en) * | 2013-12-30 | 2015-07-02 | Chiesi Farmaceutici S.P.A. | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
GB201615910D0 (en) * | 2016-09-19 | 2016-11-02 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
CN109789126A (zh) * | 2016-09-19 | 2019-05-21 | 墨西哥氟石股份公司 | 药物组合物 |
Non-Patent Citations (4)
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111983113B (zh) | 一种检测依折麦布辛伐他汀片中6-氧代辛伐他汀含量的方法 | |
CN105334274A (zh) | 枸橼酸托法替布含量及其有关物质的反相高效液相色谱法测定方法 | |
CN105424822B (zh) | 检测替格瑞洛中(1r,2s)‑2‑(3,4‑二氟苯基)环丙胺的方法 | |
CN112198260B (zh) | 一种盐酸丙卡特罗药物制剂中工艺杂质含量的检测方法 | |
CN105510482B (zh) | 一种替格瑞洛原料中异构体杂质含量的检测方法 | |
Maithani et al. | Simultaneous estimation of ambroxol hydrochloride and cetirizine hydrochloride in tablet dosage form by RP-HPLC method | |
CN112051346A (zh) | 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 | |
CN113447592A (zh) | 一种甲硝唑凝胶中乙二胺四乙酸二钠的检测方法 | |
CN109030653B (zh) | 一种左亚叶酸中有关物质的检测方法 | |
CN109142585B (zh) | 一种泛酸钠异构体的检测方法 | |
CN114324642B (zh) | 一种氢溴酸右美沙芬有关物质的测定方法 | |
CN104655757B (zh) | Bc-02的液相色谱检测方法 | |
CN115561351A (zh) | 注射用哌拉西林钠他唑巴坦钠中有关物质ⅱ的检测方法 | |
CN107884496B (zh) | 一种琥珀酸曲格列汀中琥珀酸的含量测定方法 | |
CN112881538B (zh) | 一种福多司坦及福多司坦片中杂质及对映异构体的检测方法 | |
CN117890496B (zh) | 一种复方制剂愈酚溴新口服溶液的有关物质检测方法 | |
CN110632221B (zh) | 吸入用异丙托溴铵溶液中甲酸、乙酸和丙酮的检测方法 | |
CN111521693B (zh) | 一种单硝酸异山梨酯的检测方法 | |
CN111007181A (zh) | 一种单硝酸异山梨酯的检测方法 | |
CN114280169B (zh) | 一种莫那比拉韦中异构体的测定方法 | |
CN117310022B (zh) | 一种分离和检测乌美溴铵中间体奎宁环二苯甲醇有关物质的方法 | |
CN114428131B (zh) | 一种拆分格隆溴铵中间体的非对映异构体的检测方法 | |
CN111812227B (zh) | 一种多巴丝肼复方制剂中苄丝肼杂质a的分析方法 | |
CN117741008A (zh) | 一种采用高效液相色谱法检测阿莫奈韦片中阿莫奈韦含量的方法 | |
CN118033022A (zh) | 一种盐酸丙卡特罗吸入溶液中枸橼酸含量测定的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201209 Address after: 519000 3rd and 4th floors, building 2, international health port, 628 Airport West Road, Sanzao Town, Jinwan District, Zhuhai City, Guangdong Province Applicant after: Zhuhai rispril Pharmaceutical Technology Co.,Ltd. Address before: Room 313-10, 3rd floor, aviation new town planning exhibition hall, Jinwan District, Zhuhai City, Guangdong Province Applicant before: Zhuhai Reispril Biopharmaceutical Co.,Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201208 |